Doctors Reveal the Hidden Truth About Cancer Screening | Dr. Papasotiriou & Dr. Davis | Ep. 74

In this groundbreaking episode of A Healthy Point of View, host Sam Tejada is joined by the CMO of Liquivida who is an interventional cardiologist, Dr. Christopher Davis and special guest Dr. Ioannis Papasotiriou, founder of RGCC Laboratories. Together, they dive deep into one of the most feared topics in health: cancer.

Discover how cutting-edge liquid biopsy and gene expression testing from RGCC are revolutionizing early cancer detection—even at stage ZERO. Learn why conventional screenings may be outdated, and how personalized medicine, immune system analysis, and precision therapy are the future of oncology.

Dr. Papasotiriou shares his personal journey, the power of OncoTrace and OncoDeclare tests, and the real clinical outcomes from RGCC’s work—including doubling survival time in late-stage cancers.

This episode is a must-watch for anyone serious about proactive health, cancer prevention, and living longer, healthier lives.

Learn about:

• What is advanced cancer screening?
• What is RGCC?
• The problem with late-stage diagnosis
• Dr. Davis’s experience detecting cancer early
• Comparison with traditional cancer screenings
• Personalized therapy & transcriptomics explained
• Why gene expression matters in aggressiveness & treatment
• Using AI & real-world data for drug development
• Is this the future of cancer care?
• Why RGCC avoids outside investors
• Clinical data and survival outcome
• Message to patients & doctors: Don’t give up